H.I.G. BioHealth Partners

H.I.G. BioHealth Partners is the dedicated healthcare growth-equity arm of H.I.G. Capital, targeting biopharma, devices, diagnostics, and services.

H.I.G. BioHealth Partners

H.I.G. BioHealth Partners was launched as a specialized strategy within H.I.G. Capital, the global private equity and alternative assets firm founded by Sami Mnaymneh and Tony Tamer in 1993. While the parent platform spans private equity, growth equity, real estate, and credit across more than a dozen offices worldwide, this dedicated biohealth vehicle was built to isolate life-sciences investing from the generalist deal flow — a recognition that healthcare growth requires a distinct underwriting skillset and a separate LP base comfortable with clinical and regulatory binary outcomes. The strategy targets growth-stage and late-stage companies across four verticals: biopharmaceuticals, medical devices and diagnostics, healthcare services, and digital health. Investments typically range from equity checks in the tens of millions into minority or control positions in companies that have already de-risked their core science or technology. The platform can draw on H.I.G.'s broader operational resources and portfolio-company network, which includes over 100 companies globally. The geographic mandate is primarily North America and Western Europe, with offices in Miami, New York, Boston, San Francisco, and London available to the biohealth team. Scale metrics specific to BioHealth Partners are not publicly broken out from the parent fund's reporting; H.I.G. Capital collectively reported over $65 billion in assets under management as of 2024 (per the firm, 2024). The biohealth team operates from within the larger H.I.G. Growth Partners division, which has raised several billion dollars across fund vintages. Recent activity within the broader growth platform includes closing H.I.G. Growth Partners IV at $1.0 billion in 2021. No dedicated BioHealth Partners fund close or vehicle size has been publicly disclosed. The structural differentiator is the embedded specialist model: a dedicated biohealth investment team with full underwriting autonomy but operating inside a platform that provides centralized legal, compliance, fundraising, and portfolio-operations infrastructure. This contrasts with fully independent life-sciences growth firms that must build all back-office functions themselves, and with generalist growth funds that lack the domain expertise to compete credibly for competitive healthcare deal flow.

Website

highealthbridge.com

General information

Firm type

Private Equity

Year founded

—

AUM

Undisclosed

Location

Region

North America

Country

United States

City

Miami

Corporate office

Miami, FL, United States

Sector focus

Digital HealthHealthcare ServicesBiotech & Pharma

What is the relationship between H.I.G. BioHealth Partners and H.I.G. Capital?

H.I.G. BioHealth Partners operates as a dedicated healthcare investment strategy within H.I.G. Capital, the Miami-based alternative asset manager founded in 1993. It is not a separate legal entity but functions as a specialized vertical inside the firm's broader growth-equity platform. The team benefits from H.I.G.'s centralized infrastructure, global office network, and portfolio-operations group while maintaining autonomy over healthcare investment decisions.

What investment stages does H.I.G. BioHealth Partners target?

The firm targets growth-stage and later-stage companies, typically those that have already advanced through preclinical or early clinical development and have a defined regulatory path. This de-risked posture differentiates the strategy from pure venture capital, which often backs earlier, pre-revenue science. Check sizes are not publicly disclosed but are consistent with a growth-equity mandate, likely in the $20 million to $100 million range per deal.

Which healthcare sub-sectors does H.I.G. BioHealth Partners focus on?

The firm invests across four primary verticals: biopharmaceuticals, medical devices and diagnostics, healthcare services, and digital health. Within these, the team evaluates both platform acquisitions and minority growth investments. This multi-vertical approach allows the firm to pivot between capital-intensive drug-development plays and asset-light services or technology businesses depending on the macro and regulatory environment.

How does H.I.G. BioHealth Partners source deals?

The team leverages H.I.G. Capital's network of over a dozen offices across North America, Europe, and Latin America, as well as relationships with academic medical centers, investment banks, and venture capital firms that feed later-stage opportunities. The parent firm's reputation as a reliable closing counterparty — with committed capital and no syndication risk — also generates proprietary inbound deal flow from founders and management teams seeking a partner that can fund through regulatory milestones.

Does H.I.G. BioHealth Partners raise dedicated funds?

As of the latest public records, the firm has not disclosed a dedicated standalone BioHealth Partners fund vehicle. The strategy appears to invest out of H.I.G. Growth Partners fund vintages or co-investment vehicles alongside the parent firm's generalist pool. When and if a dedicated biohealth fund is raised, that would signal institutional LPs specifically underwriting the healthcare team's track record rather than the broader growth platform's returns.

Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: Jun 3, 2026. Continuous refresh with full update cycles at least every 30 days.